BRPI0515649A - processo para preparação de composições de anticorpos altamente concentradas e processo para concentrar proteìnas - Google Patents

processo para preparação de composições de anticorpos altamente concentradas e processo para concentrar proteìnas

Info

Publication number
BRPI0515649A
BRPI0515649A BRPI0515649-1A BRPI0515649A BRPI0515649A BR PI0515649 A BRPI0515649 A BR PI0515649A BR PI0515649 A BRPI0515649 A BR PI0515649A BR PI0515649 A BRPI0515649 A BR PI0515649A
Authority
BR
Brazil
Prior art keywords
highly concentrated
concentrated antibody
antibody compositions
preparing highly
concentrating proteins
Prior art date
Application number
BRPI0515649-1A
Other languages
English (en)
Inventor
Charles Matthew Winter
Original Assignee
Genentech Inc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35996499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0515649(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Novartis Ag filed Critical Genentech Inc
Publication of BRPI0515649A publication Critical patent/BRPI0515649A/pt
Publication of BRPI0515649B1 publication Critical patent/BRPI0515649B1/pt
Publication of BRPI0515649B8 publication Critical patent/BRPI0515649B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/16—Feed pretreatment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/16—Flow or flux control
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicinal Preparation (AREA)

Abstract

"PROCESSO PARA PREPARAçãO DE COMPOSIçõES DE ANTICORPOS ALTAMENTE CONCENTRADAS E PROCESSO PARA CONCENTRAR PROTEINAS". A presente divulgação fornece um processo para concentrar proteínas incluindo ultrafiltração, diafiltração e uma segunda seqüência ultrafiltração, em temperaturas elevadas, tais como aproximadamente acima de 30<198>C. A divulgação inclui também um processo para preparar composições altamente concentradas de anticorpo e produtos de anticorpo altamente concentrados.
BRPI0515649A 2004-09-09 2005-09-08 Processo para preparação de composições de anticorpo monoclonal altamente concentradas BRPI0515649B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US60909204P 2004-09-09 2004-09-09
US60/609,092 2004-09-09
US11/220,362 US20060051347A1 (en) 2004-09-09 2005-09-06 Process for concentration of antibodies and therapeutic products thereof
US11/220,362 2005-09-06
PCT/US2005/031844 WO2006031560A2 (en) 2004-09-09 2005-09-08 Process for concentration of antibodies and therapeutic products thereof

Publications (3)

Publication Number Publication Date
BRPI0515649A true BRPI0515649A (pt) 2008-07-29
BRPI0515649B1 BRPI0515649B1 (pt) 2021-10-13
BRPI0515649B8 BRPI0515649B8 (pt) 2021-11-03

Family

ID=35996499

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515649A BRPI0515649B8 (pt) 2004-09-09 2005-09-08 Processo para preparação de composições de anticorpo monoclonal altamente concentradas

Country Status (32)

Country Link
US (6) US20060051347A1 (pt)
EP (5) EP2292636B9 (pt)
JP (2) JP5210633B2 (pt)
KR (2) KR20070109975A (pt)
CN (3) CN102911268A (pt)
AR (1) AR050641A1 (pt)
AU (1) AU2005285243C1 (pt)
BR (1) BRPI0515649B8 (pt)
CA (1) CA2577317C (pt)
DK (5) DK4108259T3 (pt)
EC (1) ECSP077282A (pt)
ES (5) ES2975166T3 (pt)
FI (4) FI3805248T3 (pt)
GT (1) GT200500254A (pt)
HU (4) HUE067296T2 (pt)
IL (2) IL181372A (pt)
LT (4) LT3805248T (pt)
MA (1) MA28991B1 (pt)
MX (2) MX342788B (pt)
MY (2) MY150549A (pt)
NO (1) NO333660B1 (pt)
NZ (1) NZ553239A (pt)
PE (1) PE20060816A1 (pt)
PL (5) PL4108259T3 (pt)
PT (5) PT3805248T (pt)
RU (1) RU2390524C2 (pt)
SG (1) SG177161A1 (pt)
SI (5) SI4104859T1 (pt)
TN (1) TNSN07069A1 (pt)
TW (1) TWI372630B (pt)
WO (1) WO2006031560A2 (pt)
ZA (1) ZA200701626B (pt)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
JP4340062B2 (ja) * 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
JP4586027B2 (ja) 2004-01-30 2010-11-24 シャイア ファーマシューティカルズ アイルランド リミテッド 組換えアリールスルファターゼａの製造及び精製
CA2566079A1 (en) 2004-05-12 2005-12-01 Terrence L. Scott Nucleic acid microspheres, production and delivery thereof
WO2005112885A2 (en) 2004-05-12 2005-12-01 Baxter International Inc. Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
US20070246406A1 (en) * 2006-03-31 2007-10-25 Dibel Kevin R Tangential flow filtration apparatuses, systems, and processes for the separation of compounds
MX2008012748A (es) 2006-04-04 2009-01-07 Shire Pharmaceuticals Ireland Un proceso para la concentracion de un polipeptido.
NZ598881A (en) * 2007-03-29 2013-11-29 Abbvie Inc Crystalline anti-human il-12 antibodies
CA2693443C (en) * 2007-07-17 2018-02-13 F. Hoffmann-La Roche Ag Variable tangential flow filtration
CN101874040A (zh) * 2007-11-29 2010-10-27 弗·哈夫曼-拉罗切有限公司 免疫球蛋白聚集体
KR20210049186A (ko) * 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
PT2271382E (pt) 2008-04-15 2013-05-07 Grifols Therapeutics Inc Ultrafiltração em dois andares/diafiltração
JP5762951B2 (ja) * 2008-05-15 2015-08-12 ダブリュ．・ヘルス・エル．ピー．Ｗ． Ｈｅａｌｔｈ Ｌ．Ｐ． 分泌性免疫グロブリンの豊富な乳画分の製造方法
US20110236391A1 (en) * 2008-12-09 2011-09-29 Hanns-Christian Mahler Method for obtaining an excipient-free antibody solution
EP2393579B1 (en) * 2009-01-21 2017-03-08 Smartflow Technologies, Inc. Optimization of separation for viscous suspensions
BRPI1006519A2 (pt) * 2009-03-06 2016-08-09 Genentech Inc formulação de anticorpos
EP2411125B1 (en) * 2009-03-24 2019-05-08 Wyeth LLC Membrane evaporation for generating highly concentrated protein therapeutics
MY157239A (en) * 2009-05-27 2016-05-13 Baxalta Inc A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
PL2483304T3 (pl) * 2009-09-29 2016-11-30 Przedfiltracyjne nastawianie substancji rozpuszczonych buforu przy wytwarzaniu immu-noglobuliny o dużym stężeniu
PT2483305T (pt) 2009-10-01 2016-11-04 Hoffmann La Roche Filtração final de imunoglobulina em várias etapas
JP6078344B2 (ja) 2010-02-04 2017-02-08 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 免疫グロブリン製剤
RS59830B1 (sr) 2010-03-01 2020-02-28 Bayer Healthcare Llc Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi)
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
EP2729566B1 (en) 2011-07-08 2017-03-15 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
KR101993488B1 (ko) 2011-09-01 2019-06-26 추가이 세이야쿠 가부시키가이샤 한외여과에 의해 고도로 농축된 항체를 포함하는 조성물의 제조 방법
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
JP2016504344A (ja) * 2012-12-28 2016-02-12 ノヴォ ノルディスク アー／エス 高温デッドエンド抗体ろ過
EP2943568B1 (en) 2013-01-09 2019-11-20 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
DE102013001628A1 (de) 2013-01-30 2014-07-31 Fresenius Medical Care Deutschland Gmbh Verfahren zur Bereitstellung eines Konzentrats
JP6661547B2 (ja) 2014-05-13 2020-03-11 アムジエン・インコーポレーテツド フィルタ及び濾過プロセスで用いるためのプロセス制御システム及び方法
EP4144434B1 (en) * 2014-06-16 2024-04-17 EMD Millipore Corporation Single-pass filtration systems and processes
US10550148B2 (en) 2014-06-16 2020-02-04 Emd Millipore Corporation Methods for increasing the capacity of flow-through processes
WO2015195452A2 (en) * 2014-06-16 2015-12-23 Emd Millipore Corporation Single-pass filtration systems and processes
EP2957335B1 (en) * 2014-06-16 2020-05-27 EMD Millipore Corporation Single-pass filtration systems and processes
CN115463546A (zh) 2014-06-25 2022-12-13 Emd 密理博公司 过滤器元件、切向流过滤系统、产生进料筛网的方法
ES2935333T3 (es) 2014-08-29 2023-03-06 Emd Millipore Corp Procesos para filtrar líquidos utilizando sistemas de filtración de flujo tangencial de paso único y sistemas de filtración de flujo tangencial con recirculación de retenido
CN105745009B (zh) 2014-08-29 2018-09-28 Emd 密理博公司 单程切向流过滤系统和具有渗余物的再循环的切向流过滤系统
IL287947B2 (en) 2014-10-23 2024-08-01 Amgen Inc Viscosity reduction of pharmaceutical preparations
HUE052280T2 (hu) 2014-12-03 2021-04-28 Csl Behring Ag Immunoglobulinokat tartalmazó megnövelt stabilitású gyógyszerészeti termék
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
AU2016329034B2 (en) * 2015-09-22 2019-05-23 Pfizer Inc. Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method
CA3023486C (en) 2016-06-09 2022-03-29 Emd Millipore Corporation Radial-path filter elements, systems and methods of using same
WO2018035116A1 (en) 2016-08-16 2018-02-22 Genzyme Corporation Methods of processing a fluid including a recombinant therapeutic protein and use thereof
SG11201901081XA (en) * 2016-08-17 2019-03-28 Boehringer Ingelheim Int Process for the preparation of highly concentrated liquid formulations containing biomolecules
ES3064802T3 (en) 2016-10-21 2026-04-29 Amgen Inc Pharmaceutical formulations and methods of making the same
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
CN107952280A (zh) * 2017-11-28 2018-04-24 安徽东方帝维生物制品股份有限公司 一种兽用疫苗无菌超滤浓缩装置及方法
WO2019132418A1 (ko) * 2017-12-27 2019-07-04 ㈜셀트리온 투석 여과 방법
MA52204A (fr) * 2018-04-12 2021-02-17 Amgen Inc Procédés de préparation de compositions protéiques stables
TWI846694B (zh) 2018-05-04 2024-07-01 美商健臻公司 具有過濾系統的灌注式生物反應器
EA202190482A1 (ru) * 2018-08-10 2021-05-25 Эмджен Инк. Способ получения фармацевтического состава на основе антитела
KR102893280B1 (ko) * 2018-08-14 2025-12-01 브리스톨-마이어스 스큅 컴퍼니 개선된 단백질 회수
TWI871300B (zh) * 2019-01-28 2025-02-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
EP3924458A1 (en) * 2019-02-15 2021-12-22 Just-Evotec Biologics, Inc. Automated biomanufacturing systems, facilities, and processes
PL3791395T3 (pl) * 2019-07-31 2022-01-24 Catalent U.K. Swindon Zydis Limited Gęstościomierz przepływowy do dozowania formulacji farmaceutycznej
CN111018968B (zh) * 2019-12-16 2021-07-27 兴盟生物医药(苏州)有限公司 一种通过超滤浓缩制备高浓度抗体制剂的方法
JP7338527B2 (ja) * 2020-03-19 2023-09-05 東レ株式会社 体液検体中のアレルゲン特異的ＩｇＥ抗体の検出方法
CN111944046B (zh) * 2020-08-28 2021-04-09 江苏荃信生物医药有限公司 高浓度、低粘度抗人il-23单克隆抗体溶液的制备方法
WO2022076318A1 (en) * 2020-10-05 2022-04-14 Bristol-Myers Squibb Company Methods for concentrating proteins
AU2021381439A1 (en) 2020-11-23 2023-06-22 Abec, Inc. Filtration systems,components and methods
US20240139685A1 (en) * 2021-03-08 2024-05-02 Nikita IKON Systems and methods for single pass counter current diafiltration
CN114014929B (zh) * 2021-11-04 2022-07-19 江苏荃信生物医药股份有限公司 一种抗人白介素-33单克隆抗体浓缩溶液的制备方法
TW202342068A (zh) 2022-02-25 2023-11-01 美商安進公司 製備高濃度液體原料藥之方法
CN115261193A (zh) * 2022-05-31 2022-11-01 利穗科技(苏州)有限公司 一种生物制品浓缩系统及其工艺
WO2024012364A1 (en) * 2022-07-12 2024-01-18 Beigene Switzerland Gmbh Preparation methods for a highly concentrated pd1 antibody solution by ultrafiltration/diafiltration (uf/df)
CN115873064A (zh) * 2022-09-27 2023-03-31 英脉生物医药(杭州)有限公司 高浓度蛋白样品的制备装置及方法
AU2024260197A1 (en) * 2023-04-25 2025-11-13 Enzene Biosciences Limited In line cleaning in place process for alternating tangential flow filter
US12030959B1 (en) 2023-07-05 2024-07-09 Genentech, Inc. Anti-IgE antibody therapy for multiple food allergies
CA3237624A1 (en) 2023-07-28 2025-04-24 Genentech, Inc. NEW USES FOR OMALIZUMAB
WO2025101602A1 (en) 2023-11-07 2025-05-15 Amgen Inc. Methods of analyzing amino acid content of a therapeutic protein
WO2026096799A1 (en) 2024-10-31 2026-05-07 Genentech, Inc. Anti-cd20 antibody formulations

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5625616B2 (pt) 1973-10-08 1981-06-13
FR2459619B1 (fr) 1979-06-26 1983-07-29 Agronomique Inst Nat Rech Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede
US4362661A (en) 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IN161706B (pt) 1983-10-05 1988-01-16 Solco Basel Ag
US4786501A (en) 1985-07-15 1988-11-22 International Minerals & Chemical Corp. Cylindrical implants for the controlled release of growth hormones
US4756696A (en) 1985-12-06 1988-07-12 Amp Incorporated Solder joint inspection feature for surface mount connectors
GB8628104D0 (en) * 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
JPS6485829A (en) 1987-09-29 1989-03-30 Aisin Aw Co Transmission for four-wheel drive vehicle
JPH01268646A (ja) 1988-04-20 1989-10-26 Meiji Milk Prod Co Ltd 抗腫瘍剤
GB2218703B (en) 1988-05-10 1992-10-28 Sumitomo Chemical Co Human monoclonal antibody to p.aeruginosa: its production and use
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US4897465A (en) 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
EP0448605A4 (en) 1988-12-15 1991-11-21 Invitron Corporation Use of basic amino acids to solubilize immunoglobulins
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
NL9001650A (nl) 1990-07-19 1992-02-17 Ver Coop Melkind Werkwijze voor de bereiding van een melkeiwit-isolaat.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5256294A (en) 1990-09-17 1993-10-26 Genentech, Inc. Tangential flow filtration process and apparatus
JP2916947B2 (ja) 1990-11-28 1999-07-05 興和株式会社 Ｃｐｂ―ｉの安定化方法及び製剤組成物
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
JP2907603B2 (ja) * 1991-09-09 1999-06-21 雪印乳業株式会社 新規生理活性ペプチド、該活性ペプチドを有効成分とする胃酸分泌抑制剤、抗潰瘍剤及び飲食品
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5707678A (en) 1995-04-12 1998-01-13 Galagen Inc. Method for microfiltration of milk or colostral whey
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
DE19543737A1 (de) 1995-11-24 1997-05-28 Hoechst Ag Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
JP2001516599A (ja) * 1997-09-22 2001-10-02 セプラジェン コーポレーション ホエータンパク質の逐次分離およびその配合物
RU2140287C1 (ru) * 1998-08-25 1999-10-27 Государственное унитарное предприятие "Иммунопрепарат" Способ получения альбумина
WO2000024266A2 (en) 1998-10-26 2000-05-04 Galagen, Inc. Soy and immunoglobulin compositions
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
AR024676A1 (es) 1999-07-07 2002-10-23 New Zealand Co Operative Dairy Company Ltd Metodos para obtener aislados de proteina y concentrados de calostro
CN1245216C (zh) 1999-10-04 2006-03-15 希龙公司 稳定化的含多肽的液体药物组合物
JP5485489B2 (ja) * 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
ES2184594B1 (es) 2001-01-17 2004-01-01 Probitas Pharma Sa Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
AU2002324556A1 (en) 2001-07-25 2003-02-17 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
ES2392073T3 (es) 2001-11-08 2012-12-04 Abbott Biotherapeutics Corp. Formulación farmacéutica líquida estable de anticuerpos IGG
EP1450847B1 (en) * 2001-11-13 2010-09-29 Genentech, Inc. APO2 ligand/ TRAIL formulations and uses thereof
SI1478394T1 (sl) 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
EP1551875A4 (en) * 2002-06-21 2006-06-28 Biogen Idec Inc TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
JP4500683B2 (ja) * 2002-11-01 2010-07-14 バイエル・ヘルスケア・エルエルシー 巨大分子濃縮方法
GB0229444D0 (en) 2002-12-18 2003-01-22 Royal Free Hampstead Nhs Trust Diagnostic method and assay kit
JP2006515227A (ja) * 2003-02-24 2006-05-25 ジーティーシー バイオセラピューティックス インコーポレイテッド 十字流濾過の方法およびそのための装置
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
MXPA06008435A (es) 2004-01-30 2007-05-23 Suomen Punainen Risti Veripalvelu Proceso de manufactura de una inmunoglobulina libre de virus.
US20080247991A1 (en) 2004-02-26 2008-10-09 Trout Bernhardt L Solution Additives For the Attenuation of Protein Aggregation
US8471757B2 (en) 2004-08-19 2013-06-25 Electronic Navigation Research Institute, An Independent Administrative Institution Device using dielectric lens
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JP6044754B2 (ja) 2012-01-19 2016-12-14 株式会社ジェイテクト クラッチプレートおよびその製造方法
US11220362B2 (en) 2017-08-16 2022-01-11 O & M Halyard, Inc. Method and system for wrapping ties in a facemask manufacturing process

Also Published As

Publication number Publication date
IL216851A0 (en) 2012-01-31
SI4104859T1 (sl) 2024-08-30
ES2942574T3 (es) 2023-06-02
CN104961797A (zh) 2015-10-07
MA28991B1 (fr) 2007-11-01
CN101056885A (zh) 2007-10-17
US20060051347A1 (en) 2006-03-09
KR101528970B9 (ko) 2022-12-09
RU2390524C2 (ru) 2010-05-27
US12371510B2 (en) 2025-07-29
JP2008512473A (ja) 2008-04-24
US20070237762A1 (en) 2007-10-11
PE20060816A1 (es) 2006-09-02
CN101056885B (zh) 2015-08-26
SG177161A1 (en) 2012-01-30
HUE065025T2 (hu) 2024-04-28
DK4108259T3 (da) 2024-03-11
IL181372A (en) 2012-01-31
SI4108259T1 (sl) 2024-04-30
SI1786830T1 (sl) 2015-03-31
SI3805248T1 (sl) 2023-05-31
JP5426641B2 (ja) 2014-02-26
MX342788B (es) 2016-10-12
LT4104859T (lt) 2024-07-10
KR20120135530A (ko) 2012-12-14
PL4104859T3 (pl) 2024-08-26
CN104961797B (zh) 2020-12-25
KR20070109975A (ko) 2007-11-15
EP4104859A1 (en) 2022-12-21
ZA200701626B (en) 2008-10-29
AU2005285243C1 (en) 2012-10-25
NZ553239A (en) 2009-11-27
EP4108259B1 (en) 2024-01-03
AR050641A1 (es) 2006-11-08
MX2007002812A (es) 2007-05-16
FI3805248T3 (fi) 2023-04-21
EP3805248B1 (en) 2023-01-18
PT1786830E (pt) 2015-02-05
MY150549A (en) 2014-01-30
HUE067662T2 (hu) 2024-11-28
PT4104859T (pt) 2024-07-02
LT3805248T (lt) 2023-04-25
WO2006031560A2 (en) 2006-03-23
JP5210633B2 (ja) 2013-06-12
US20090214522A1 (en) 2009-08-27
LT4108259T (lt) 2024-04-10
PL2292636T3 (pl) 2024-03-11
US20230074486A1 (en) 2023-03-09
CA2577317C (en) 2016-04-26
IL181372A0 (en) 2007-07-04
EP2292636A3 (en) 2013-05-01
AU2005285243B2 (en) 2012-03-08
TNSN07069A1 (en) 2008-06-02
DK3805248T3 (da) 2023-04-03
EP4108259A1 (en) 2022-12-28
AU2005285243A1 (en) 2006-03-23
FI4108259T3 (fi) 2024-09-10
PT2292636T (pt) 2024-01-09
US20210095050A1 (en) 2021-04-01
FI4104859T3 (fi) 2024-07-16
JP2012097086A (ja) 2012-05-24
HUE061899T2 (hu) 2023-08-28
EP3805248A2 (en) 2021-04-14
GT200500254A (es) 2006-08-02
US11767370B2 (en) 2023-09-26
EP2292636A2 (en) 2011-03-09
NO20071432L (no) 2007-03-16
NO333660B1 (no) 2013-08-05
EP3805248A3 (en) 2021-07-14
HK1101249A1 (en) 2007-10-12
EP4104859B1 (en) 2024-04-17
DK2292636T3 (da) 2024-01-15
ES2968070T3 (es) 2024-05-07
EP1786830B1 (en) 2014-11-12
US20140370003A1 (en) 2014-12-18
HK1215869A1 (zh) 2016-09-23
EP1786830A2 (en) 2007-05-23
DK4104859T3 (da) 2024-07-08
PT3805248T (pt) 2023-04-05
KR101528970B1 (ko) 2015-06-15
WO2006031560A3 (en) 2006-08-24
PL3805248T3 (pl) 2023-05-22
ES2983099T3 (es) 2024-10-22
TWI372630B (en) 2012-09-21
CA2577317A1 (en) 2006-03-23
US10370456B2 (en) 2019-08-06
FI2292636T3 (fi) 2024-01-12
CN102911268A (zh) 2013-02-06
BRPI0515649B1 (pt) 2021-10-13
HUE067296T2 (hu) 2024-10-28
ES2528541T3 (es) 2015-02-10
SI2292636T1 (sl) 2024-02-29
DK3805248T5 (da) 2023-04-24
LT2292636T (lt) 2024-01-10
RU2007110534A (ru) 2008-10-20
BRPI0515649B8 (pt) 2021-11-03
PT4108259T (pt) 2024-03-07
MY162525A (en) 2017-06-15
DK1786830T3 (en) 2015-01-19
ECSP077282A (es) 2007-03-29
PL1786830T3 (pl) 2015-05-29
EP2292636B1 (en) 2023-10-18
EP2292636B9 (en) 2024-01-03
PL4108259T3 (pl) 2024-05-13
TW200612989A (en) 2006-05-01
ES2975166T3 (es) 2024-07-03

Similar Documents

Publication Publication Date Title
BRPI0515649B8 (pt) Processo para preparação de composições de anticorpo monoclonal altamente concentradas
ES2353814T3 (es) Proteinas n-glicosiladas recombinantes de celulas procariotas.
AR057614A1 (es) Composiciones y metodos para producir moleculas de union con antigeno hibridas y usos de las mismas
BR112012012460A8 (pt) método de liofilização, composições e kits
UA103176C2 (ru) Растение с повышенными показателями урожайности и способ его получения
NZ584893A (en) PORCINE DC-SIGN, ICAM-3 AND LSECtin AND USES THEREOF
CY1109722T1 (el) Ενδιαμεσες ενωσεις για την παρασκευη της trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,73oxepino[4,5-c]pyrrole
CL2008003794A1 (es) Virus de la estomatitis vesicular geneticamente modificado (vsv) que comprende por lo menos una mutacion de aminoacido en una region de alguna de las proteinas m, g y l del virus; metodo para producirlo; composicion inmunogenica que lo comprende; metodo para adaptar un virus en un cultivo celular.
MY206284A (en) Anti-cd63 antibodies, conjugates, and uses thereof
DK1893587T3 (da) Fremgangsmåde til fremstilling af dihydroquinazoliner
MX2009004435A (es) Tinturas dispersas, su preparacion y su uso.
WO2013102211A3 (en) Stabilized antiviral fusion helices
BRPI0508610A (pt) derivados de aminoácidos
EP4374913A3 (en) Novel human serum albumin mutant
MX2009007572A (es) Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y.
TR200400639T4 (tr) Donmaya-karşı proteinler, bunların üretimleri ve kullanımları
DE602005020185D1 (de) Verfahren zur herstellung von 17-hydroxy-6 beta, 7 beta, 15 beta,16 beta-bismethylen-17alpha-pregn-4henprodukte für dieses verfahren
EA200701852A1 (ru) Производные аминокислот
BRPI0910882A2 (pt) Processo para purificar hidrolisado de proteína derivado de heparina enzimaticamente digerido, hidrolisado de proteína derivado de heparina enzimaticamente digerido purificado, uso do mesmo, e, produtos alimentício e fertilizante.
ATE528278T1 (de) Herstellung von 2-(1,3-dimethylbutyl)anilin und anderen verzweigten, alkylsubstituierten anilinen
CY1126762T1 (el) Διαδικασια για τη συμπυκνωση αντισωματων και θεραπευτικων προϊοντων αυτων
JOP20050124B1 (ar) عملية تركيز الاجسام المضادة والمنتجات العلاجية منها
ATE451345T1 (de) Verfahren zur herstellung von optisch aktiven 3- phenylpropionsäurederivaten und folgeprodukte davon
BRPI0409644A (pt) processo para a preparação de nicotinaldeìdos
BR0311761A (pt) Processo para a preparação de 4,6-dicloro-5-fluorpirimidina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/09/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE AO DESPACHO 16.1 PUBLICADO NA RPI 2649, QUANTO AO ENDERECO DO TITULAR